Teva Pharmaceutical Industries (FRA:TEV) Altman Z2-Score: -0.41 (As of Jul. 07, 2026)


FRA:TEV Teva Pharmaceutical Industries Ltd FRA:TEV
60 GF Score
Price €30.60
GF Value €17.78
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Altman Z2-Score?

Teva Pharmaceutical Industries FRA:TEV +2.68% 60 Altman Z2-Score is -0.41 as of Jul. 07, 2026. GuruFocus rates FRA:TEV with a GF Score™ of 60/100 and a GF Value™ of €17.78 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 996 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks worse than 77.61% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Teva Pharmaceutical Industries has a Altman Z2-Score of -0.41, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Teva Pharmaceutical Industries's Altman Z2-Score or its related term are showing as below:

FRA:TEV' s Altman Z2-Score Range Over the Past 10 Years
Min: -1.8   Med: -0.69   Max: 2.68
Current: -0.41

During the past 13 years, Teva Pharmaceutical Industries's highest Altman Z2-Score was 2.68. The lowest was -1.80. And the median was -0.69.


Teva Pharmaceutical Industries  (FRA:TEV) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Teva Pharmaceutical Industries Altman Z2-Score Related Terms


Teva Pharmaceutical Industries Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Altman Z2-Score Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.98 -0.69 -1.18 -0.42

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.92 -0.71 -0.42 -0.42 -0.41

FRA:TEV vs ZTS, UTHR, VTRS: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Altman Z2-Score falls into.


FRA:TEV
60GF Score
Teva Pharmaceutical Industries Ltd FRA:TEV
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Teva Pharmaceutical Industries's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0044+3.26*-0.3345+6.72*0.0563+1.05*0.2587
=-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was €34,635 Mil.
Total Current Assets was €11,859 Mil.
Total Current Liabilities was €11,705 Mil.
Retained Earnings was €-11,586 Mil.
Pre-Tax Income was 378.005 + 68.32 + 550.392 + 176.001 = €1,173 Mil.
Interest Expense was -173.865 + -249.368 + -178.068 + -176.001 = €-777 Mil.
Total Liabilities was €27,514 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(11859.15 - 11705.18)/34634.6
=0.0044

X2=Retained Earnings/Total Assets
=-11585.81/34634.6
=-0.3345

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(1172.718 - -777.302)/34634.6
=0.0563

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(7117.22 - 0)/27513.92
=0.2587

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Teva Pharmaceutical Industries has a Altman Z2-Score of -0.41 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -0.41 mean?
Teva Pharmaceutical Industries (FRA:TEV) has a Altman Z2-Score of -0.41 as of Jul. 07, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Teva Pharmaceutical Industries and its competitors. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #773 out of 996 companies in the Drug Manufacturers industry, placing it in the top 77.6%.
Is Teva Pharmaceutical Industries' Altman Z2-Score too high?
Teva Pharmaceutical Industries' current Altman Z2-Score is -0.41. Based on the distribution chart, Teva Pharmaceutical Industries ranks #773 out of 996 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Teva Pharmaceutical Industries has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #773 out of 996 companies for Altman Z2-Score. This places Teva Pharmaceutical Industries in the lower half of its industry. The industry median Altman Z2-Score is 3.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.87, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current Altman Z2-Score is -0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.78, compared to a current price of €30.60 — trading 72.1% above its estimated fair value. The current Altman Z2-Score is -0.41. Teva Pharmaceutical Industries' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Altman Z2-Score is -0.41 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of €30.60 is trading 72.1% above its estimated GF Value™ of €17.78. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for FRA:TEV:

  • Altman Z2-Score: -0.41
  • GF Value™: €17.78 vs. price of €30.60 (72.1% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
60GF Score

Get the complete analysis for FRA:TEV

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.60
Price
€17.78
GF Value